We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
AbCellera Biologics Inc. (ABCL - Free Report) reported $9.18 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 57.4%. EPS of -$0.17 for the same period compares to -$0.10 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $9.58 million, representing a surprise of -4.19%. The company delivered an EPS surprise of -21.43%, with the consensus EPS estimate being -$0.14.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how AbCellera Biologics Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Research fees: $8.74 million versus $8.34 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -23.5% change.
Revenue- Licensing: $0.19 million versus $0.32 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.1% change.
Revenue- Milestone payments: $0.25 million versus $1.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -50% change.
Shares of AbCellera Biologics Inc. have returned -3.1% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
AbCellera Biologics Inc. (ABCL - Free Report) reported $9.18 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 57.4%. EPS of -$0.17 for the same period compares to -$0.10 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $9.58 million, representing a surprise of -4.19%. The company delivered an EPS surprise of -21.43%, with the consensus EPS estimate being -$0.14.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how AbCellera Biologics Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Research fees: $8.74 million versus $8.34 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -23.5% change.
- Revenue- Licensing: $0.19 million versus $0.32 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.1% change.
- Revenue- Milestone payments: $0.25 million versus $1.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -50% change.
View all Key Company Metrics for AbCellera Biologics Inc. here>>>Shares of AbCellera Biologics Inc. have returned -3.1% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.